Page 4 - Drug Development Summit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ASLAN Pharmaceuticals (ASLN) Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models

ASLAN Pharmaceuticals (ASLN) Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCarl firthShawn kwatra johns hopkinsFerda cevikbasPrecedence researchWorld health organizationAslan pharmaceuticals nasdaqDr madan kwatra duke universityInternational society of investigative dermatology meetingDrug development summitDermatology drug development summitJohns hopkins medicineDuke universityChief executive officerTranslational scienceInternational society

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity

– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors –

United statesAlexandra weingartenFrancis burrowsCorporate communicationsExchange commissionCompany formDrug development summitKura oncology incTranslational researchTargeted drug development summitTransferase inhibitorsOvercoming adaptive resistanceTargeted therapiesSenior vice presidentVice presidentInvestor relations

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovarian Cancer Efficacy Data .

United statesCity ofUnited kingdomUdai banerjiDan patersonJonathan pachterLouis denisInstitute of cancer researchDrug development unitDrug administrationRaf and mek programAmerican society of clinical oncologyDrug development summitVerastem oncologyTargeted drug development summitChief scientific officer

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

28.09.2023 - – Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to include KRASG12C-mutant NSCLC in combination portion of Phase 1 clinical trial of KO-2806 (FIT-001) – SAN DIEGO, . Seite 1

United statesFrancis burrowsKura oncology incDrug development summitTranslational researchTargeted drug development summitOvercoming adaptive resistanceTargeted therapiesSenior vice presidentKura oncology chartUra oncology kursUra oncology aktie

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomLouis denisDan patersonElisa buffingtonRyan porterDan calkinsUdai banerjiJonathan pachterDrug development summitDrug administrationAmerican society of clinical oncologyCorporate communicationsInstitute of cancer researchDrug development unit